Minerva Surgical, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Darin Hammers
- Full Time Employees
- 174
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 4255 Burton Drive Santa Clara CA United States of America 95054
- IPO Date
- Oct 22, 2021
- CIK
- 0001452965
- Website
- minervasurgical.com
- Similar Companies
- Business
- Minerva Surgical, Inc. (NasdaqCM: UTRS) develops and commercializes minimally invasive endometrial ablation devices for the treatment of heavy menstrual bleeding. The company offers the Genesys HTA system, a second-generation endometrial ablation technology that utilizes heated fluid to ablate the uterine lining in an automated, controlled process; the Sonata system, which employs intrauterine ultrasound-guided radiofrequency ablation for targeted tissue destruction; and the Cerene Cryotherapy Device, a cryotherapy-based solution for endometrial ablation performed in-office with minimal anesthesia. These products target gynecologists and healthcare providers serving women seeking non-surgical alternatives to hysterectomy, primarily in the United States with expanding operations in Europe and select international markets. Founded in 2006 and headquartered in Redwood City, California, Minerva Surgical focuses on the women's health segment of the medical device industry. In late 2024, the company underwent a significant strategic shift through its acquisition by Boston Scientific Corporation, enhancing its market reach and integrating its ablation portfolio into a broader lineup of gynecology solutions; this transaction followed a period of independent innovation, including regulatory clearances for next-generation devices within the prior two years.
Financial Contrast: Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) vs. Minerva Surgical (NASDAQ:UTRS)
INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS) Head-To-Head Analysis
T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review
Head to Head Analysis: InspireMD (NYSE:NSPR) versus Minerva Surgical (NASDAQ:UTRS)
Why Is Minerva Surgical (UTRS) Stock Down 50% Today?
Minerva Surgical Reports Third Quarter 2023 Financial Results
Minerva Surgical, Inc. (UTRS) Q2 2023 Earnings Call Transcript
Minerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates
Minerva Surgical Reports Second Quarter 2023 Financial Results
The Main Differences Between Penny Stocks and Blue Chips
Best Penny Stocks Today? 3 Under $1 To Watch Now
Why Is Minerva Surgical (UTRS) Stock Up 229% Today?
Minerva Surgical, Inc. (UTRS) Q1 2023 Earnings Call Transcript
Minerva Surgical to Announce First Quarter 2023 Financial Results
Minerva Surgical, Inc. (UTRS) Q4 2022 Earnings Call Transcript
Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference
Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference
Minerva Surgical, Inc. (UTRS) Q3 2022 Earnings Call Transcript
Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call